英文名稱(chēng) | Osilodrostat (LCI699) |
---|---|
中文名稱(chēng) | 奧西卓司他 |
CAS號(hào) | 928134-65-0 |
分子式 | C13H10FN3 |
分子量 | 227.24 |
外觀 | White to yellow pwder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | 3-5days | ¥350.00 | 登錄后可見(jiàn) | |
5 mg | 3-5days | ¥660.00 | 登錄后可見(jiàn) | |
10 mg | 3-5days | ¥1150.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Osilodrostat (LCI699) |
---|---|
中文名稱(chēng) | 奧西卓司他 |
CAS號(hào) | 928134-65-0 |
分子式 | C13H10FN3 |
分子量 | 227.24 |
外觀 | White to yellow pwder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Osilodrostat, also known as LCI699, is a potent inhibitor of 11β-hydroxylase, the enzyme which catalyzes the final step of cortisol synthesis. LCI699 may thus be a potential new treatment for all forms of Cushing's syndrome. Current evidence indicates that the novel aldosterone inhibitor LCI699 is an effective and well-tolerated antihypertensive agent that lowers plasma aldosterone concentration and produces a mild ACTH-stimulated cortisol response suppressive effect.